Ace Therapeutics assists in the development of drug delivery systems (DDS) for the treatment of H. pylori and provides development services for pH-sensitive DDS. We offer to develop pH-sensitive DDS in two aspects. One is to develop DDS that release drugs in a pH-neutral environment, and the other is to develop DDS that act in an acidic environment to play an adjunctive therapeutic role.
Development of DDS that release drugs in a pH-neutral environment
When the pH in the gastric environment is 6-7, H. pylori enters the replication phase and this is the best time to use antibiotics to treat H. pylori. We offer pH-sensitive drug delivery system development services to release antibiotics at the right time to treat H. pylori.
Development of pH-sensitive DDS using acidic and basic amino acids
Ace Therapeutics offers services to modify nanoparticles (such as chitosan nanoparticles) using acidic amino acids (aspartate and glutamate) and basic amino acids (histidine, lysine, and arginine). The amide bond in the peptide chain can act as a donor and an acceptor for hydrogen bonding. The use of acidic and basic amino acids together can design zwitterionic polypeptides for a variety of biological functions. We offer to modify the nano delivery system with acidic amino acids as the primary and basic amino acids as the secondary. The modified delivery system is positively charged with the help of basic amino acids and targets H. pylori for transport. Then, in a neutral environment, the acidic amino acids affect the stability of the nano delivery system allowing the drug to be released around H. pylori.
Development of pH-sensitive DDS using chitosan-modified gold nanoparticles and anionic liposomes
We offer the development of DDS using chitosan-modified gold nanoparticles and anionic liposomes. The structure is shown in Fig. 1. Chitosan-modified gold nanoparticles are positively charged in an acidic environment, and their covalent binding to negatively charged liposomes allows for acidic environment stabilization. When in a neutral environment, the chitosan is deprotonated. The chitosan-modified gold nanoparticles are separated from the liposomes, and the exposed liposomes fuse with the H. pylori cell membrane to release the drug.
Fig. 1 Drug delivery systems using chitosan-modified gold nanoparticles and anionic liposomes.
Development of DDS that act in an acidic environment
H. pylori has only one antioxidant system, the thioredoxin (Trx) system. We offer to develop nanozymes delivery systems that act like peroxidase or oxidase in the gastric acid environment to assist in killing H. pylori. Current research has identified metal, metal oxide, and carbon nanozymes with peroxidase activity and Ru, Au@Pt, CeO2, and N-CNMs nanozymes with oxidase activity. We offer size optimization and surface modification (using organic molecules or polymers) of the nanozymes so that they exert a higher activity in the acidic environment of the stomach, while activity is inhibited in the neutral environment.
Contact us
Ace Therapeutics offers two aspects of pH-sensitive drug delivery system development services to release H. pylori drugs at the appropriate time. If you would like to know more about these drug delivery system development services, please contact us.
Reference
- Yang, W.; et al. Nanozymes: Activity origin, catalytic mechanism, and biological application. Coordination Chemistry Reviews. 2021, 448: 214170.
※ All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
